skip to Main Content

New Combination Therapy Could Help Fight Difficult-to-Treat Cancers with Common Mutations

Newsfeed image, light gray text on dark gray background

Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.

Now, scientists at the UCLA Jonsson Comprehensive Cancer Center describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. Read more . .  

Back To Top